Mifepristone Linepharma

Mifepristone, the active ingredient in Mifepristone Linepharma, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is employed for the medical termination of intrauterine pregnancy in women seeking a non‑surgical option.

GNH USA supplies Mifepristone Linepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifepristone acts on the progesterone pathway to facilitate termination of early pregnancy. It is used in the following clinical situations: - Medical termination of intrauterine pregnancy: induces abortion when combined with a prostaglandin analogue. - Early pregnancy termination up to 10 weeks gestation: provides a non‑surgical option for women. - Cushing syndrome (off‑label): may be used to control hypercortisolism in selected patients.

Mifepristone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes after dosing. - Abdominal pain or cramping: typical uterine discomfort. - Diarrhea: loose stools in some patients. - Fatigue: feeling of tiredness. - Headache: transient head pain.

Serious or Rare Side Effects: - Heavy vaginal bleeding: may require medical attention. - Infection: signs of fever or pelvic infection. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver toxicity: elevated enzymes or jaundice. - Uterine rupture: extremely rare but critical emergency.

Mifepristone should be used under strict medical supervision with attention to several safety considerations. - Confirm gestational age: ensure pregnancy is within approved limits. - Exclude ectopic pregnancy: perform ultrasound before administration. - Assess adrenal function: avoid in patients with chronic adrenal insufficiency. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Contraindicated in concurrent use of anticoagulants without monitoring. - Store at below 25°C: keep in the original pack, protect from moisture.

Mifepristone can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that reduces mifepristone levels. - Carbamazepine: enzyme inducer decreasing drug exposure. - St. John’s wort: herbal inducer that may lower efficacy.

Moderate Interactions (Monitor Closely): - Ketoconazole: CYP3A4 inhibitor that can increase mifepristone concentrations. - Efavirenz: antiretroviral that may modestly reduce drug levels. - Anticoagulants (e.g., warfarin): may enhance bleeding risk; monitor coagulation parameters.